🇺🇸 (LMW)heparin in United States

17 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 17

Most-reported reactions

1. Caesarean Section — 3 reports (17.65%)
2. Drug Exposure During Pregnancy — 3 reports (17.65%)
3. Foetal Disorder — 2 reports (11.76%)
4. Intra-Uterine Death — 2 reports (11.76%)
5. Thrombosis — 2 reports (11.76%)
6. Abortion Induced — 1 report (5.88%)
7. Acute Pulmonary Oedema — 1 report (5.88%)
8. Alanine Aminotransferase Increased — 1 report (5.88%)
9. Anaemia Haemolytic Autoimmune — 1 report (5.88%)
10. Antepartum Haemorrhage — 1 report (5.88%)

Source database →

Frequently asked questions

Is (LMW)heparin approved in United States?

(LMW)heparin does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for (LMW)heparin in United States?

Sanofi is the originator. The local marketing authorisation holder may differ — check the official source linked above.